The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Does Switching from IV to Subcutaneous Tocilizumab Affect RA Disease Flare?

Does Switching from IV to Subcutaneous Tocilizumab Affect RA Disease Flare?

December 9, 2021 • By Michele B. Kaufman, PharmD, BCGP

  • Tweet
  • Email
Print-Friendly Version / Save PDF
ajt/shutterstock.com

ajt/shutterstock.com

ACR CONVERGENCE 2021—Tocilizumab (Actemra) is a recombinant humanized monoclonal antibody of the interleukin (IL) 6 receptor that inhibits IL-6-mediated signaling.1 IL-6 is a key player in immune and inflammatory responses. Recent research evaluated the incidence and risk factors for flares after switching patients with rheumatoid arthritis (RA) who were stable on intravenous (IV) tocilizumab therapy to subcutaneous tocilizumab. Soo Min Ahn, MD, from the Asan Medical Center, Seoul, South Korea, presented these data during ACR Convergence 2021, held Nov. 3–9.2

You Might Also Like
  • FDA Approves Subcutaneous Tocilizumab for Ages 2–17
  • Alendronate May Provide Cardiovascular Benefits; Plus FDA Approves Subcutaneous Tocilizumab
  • FDA Approves Tocilizumab to Treat Systemic Sclerosis-Associated ILD
Explore This Issue
February 2022
Also By This Author
  • FDA Approves Baricitinib for RA Patients

Background: On Jan. 8, 2010, the U.S. Food & Drug Administration (FDA) approved tocilizumab in an intravenous injection to treat adults with moderate to severe active RA for whom one or more tumor necrosis factor antagonists have proved inadequate.3 On Oct. 21, 2013, a subcutaneous form of tocilizumab was approved. Current FDA-approved indications for tocilizumab include RA, giant cell arteritis, systemic sclerosis-associated interstitial lung disease, polyarticular juvenile idiopathic arthritis and cytokine release syndrome.4 Tocilizumab is also approved throughout the world for numerous indications.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Dr. Ahn and colleagues retrospectively evaluated the incidence of RA flares in patients from a single tertiary hospital who had switched from IV tocilizumab to subcutaneous tocilizumab between January 2013 and April 2020. The patients were divided into two groups—the subcutaneous-inefficacy group and the subcutaneous-efficacy group—based on their RA Disease Activity Score in 28 joints (DAS28) after switching to subcutaneous tocilizumab. Factors associated with RA flares were evaluated by multivariate analysis.

The Results

Researchers identified 147 patients who were initially treated with IV tocilizumab and subsequently achieved remission or low disease activity. Of these patients, 37 were switched to subcutaneous tocilizumab. At the time of switching, the mean DAS28 did not differ between the two groups (2.46 for the subcutaneous-inefficacy group vs. 2.17 for the subcutaneous-efficacy group). The subcutaneous-inefficacy group had 11 patients (29.7%), all women, and the subcutaneous-efficacy group had 26 patients (70.3%), 81% of whom were women (n=21). The median disease duration of patients in the subcutaneous-efficacy group was 138 months (36–160) and 92 months (51–181) in the subcutaneous-efficacy group. IV tocilizumab doses per weight and methotrexate doses were higher in the subcutaneous-inefficacy group.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

In the multivariate analysis, the use of more than 8 mg/kg tocilizumab, which is considered a high dose, non-use of methotrexate and a history of prior abatacept treatment were associated with the risk of RA flares after switching to subcutaneous tocilizumab.

These study results led the authors to recommend clinicians examine these factors prior to switching patients from IV tocilizumab to subcutaneous tocilizumab to prevent RA flares.

Pages: 1 2 | Single Page

Filed Under: ACR Convergence, DMARDs & Immunosuppressives, Drug Updates, Meeting Reports Tagged With: ACR Convergence 2021, ACR Convergence 2021 – RA, IV tocilizumab, RA flares, subcutaneous tocilizumab, tocilizumabIssue: February 2022

You Might Also Like:
  • FDA Approves Subcutaneous Tocilizumab for Ages 2–17
  • Alendronate May Provide Cardiovascular Benefits; Plus FDA Approves Subcutaneous Tocilizumab
  • FDA Approves Tocilizumab to Treat Systemic Sclerosis-Associated ILD
  • China Approves Use of Tocilizumab for Coronavirus Patients

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2022 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.